TTM
-139.0%
YoY change
+31.94pp
Trough year (2018)
-3001.3%
Peak year (2009)
1159.9%
Latest annual
-193.2%
EBITDA Margin history chart for Insmed (INSM) from 2002 to 2025
Latest: -193.2%
EBITDA Margin change chart for Insmed (INSM) from 2002 to 2025
Latest: +31.94pp
EBITDA Margin history table for Insmed (INSM) from 2002 to 2025
| 2025 | -193.2% | +31.94pp | ||
| 2024 | -225.1% | -8.82pp | ||
| 2023 | -216.3% | -33.97pp | ||
| 2022 | -182.3% | +21.24pp | ||
| 2021 | -203.6% | -51.29pp | ||
| 2020 | -152.3% | +6.78pp | ||
| 2019 | -159.1% | +2842.24pp | ||
| 2018 | -3001.3% | — | ||
| 2014 | -748.6% | -277.31pp | ||
| 2013 | -471.3% | — | ||
| 2011 | -1342.8% | -1253.31pp | ||
| 2010 | -89.5% | -1249.37pp | ||
| 2009 | 1159.9% | +1274.15pp | ||
| 2008 | -114.3% | +151.81pp | ||
| 2007 | -266.1% | — | ||
| 2002 | -1746.5% | — |
- 2025-193.2%+31.94pp
- 2024-225.1%-8.82pp
- 2023-216.3%-33.97pp
- 2022-182.3%+21.24pp
- 2021-203.6%-51.29pp
- 2020-152.3%+6.78pp
- 2019-159.1%+2842.24pp
- 2018-3001.3%—
- 2014-748.6%-277.31pp
- 2013-471.3%—
- 2011-1342.8%-1253.31pp
- 2010-89.5%-1249.37pp
- 20091159.9%+1274.15pp
- 2008-114.3%+151.81pp
- 2007-266.1%—
- 2002-1746.5%—
EBITDA Margin values are taken from Insmed's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA Margin at Insmed (INSM)
According to Insmed's latest reported financial statements, the company's latest reported EBITDA margin is -139.0%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Insmed (INSM) EBITDA margin is -193.18% – expanded 31.9 percentage points year-over-year.
The record annual EBITDA margin stands at 1159.89%, reached in 2009; the historical low of -3001.30% was recorded in 2018.
Insmed EBITDA Margin by Year
Insmed EBITDA Margin 2025: -193.2%
In 2025, Insmed reported EBITDA margin of -193.18%, expanded 31.9 percentage points from 2024.
Insmed EBITDA Margin 2024: -225.1%
Insmed EBITDA margin in 2024 was -225.12%, contracted 8.8 percentage points from 2023.
Insmed EBITDA Margin 2023: -216.3%
2023's EBITDA margin for Insmed came in at -216.30%, contracted 34.0 percentage points from 2022.
Insmed EBITDA Margin 2022: -182.3%
Insmed posted EBITDA margin of -182.33% in 2022, expanded 21.2 percentage points from 2021.
Insmed EBITDA Margin 2021: -203.6%
Insmed EBITDA margin in 2021 was -203.57%.
See more financial history for Insmed (INSM).
Sector peers by EBITDA Margin
Healthcare peers of Insmed (INSM), ranked by their latest EBITDA margin
| 55.4% | |
| 46.6% | |
| 45.9% | |
| 34.6% | |
| 33.9% | |
| 30.3% | |
| 26.9% | |
| 5.1% |
- 55.4%
- 46.6%
- 45.9%
- 34.6%
- 33.9%
- 26.9%
Frequently asked questions
Insmed (INSM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation